CRVS — Corvus Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1626971 ·
Last close
$10.17
Market Cap
$857.87M
52W High
$26.95
52W Low
$6.39
ADV30
1,036,776
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -21,362,000 | -20,343,000 | 223,878,000 | 15,013,000 | 15,557,000 |
| Jun 2026 | 0 | — | -19,297,000 | -17,959,000 | 239,274,000 | 18,905,000 | 13,946,000 |
| Mar 2026 | 0 | — | -14,877,000 | -13,692,000 | 253,195,000 | 40,102,000 | 12,516,000 |
| Dec 2025 | 0 | — | -12,217,000 | -12,321,000 | 71,119,000 | 4,576,000 | 9,914,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-44,529,000
Investing CF
$-142,549,000
Financing CF
$191,292,000
CapEx
$-811,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,944,000
Inventory
—
Receivables
$1,849,000
ST Investments
$196,323,000
EBIT TTM
$-56,963,000
Pretax Income TTM
$-54,129,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -42,971,000 | -15,283,000 | 71,119,000 | 9,914,000 | 61,205,000 | -32,797,000 |
| Dec 2024 | 0 | -27,548,000 | -62,293,000 | 68,907,000 | 36,339,000 | 32,568,000 | -25,424,000 |
| Dec 2023 | 0 | -23,407,000 | -27,029,000 | 45,553,000 | 6,869,000 | 38,684,000 | -23,935,000 |
| Dec 2022 | 0 | -32,565,000 | -41,307,000 | 68,240,000 | 12,125,000 | 56,115,000 | -27,023,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-54,129,000
OpCashFlow TTM
—
Assets (Latest)
$239,274,000
Forward EPS
$-1.07
Max Pain — expiry 2028-01-21
max pain strike: $20.00 · spot: $10.19 · call oi: 0 · put oi: 1,627
Expected Move to 2028-01-21:
±$9.90
(97.15%) —
implied range
$0.29 –
$20.09
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHAR | Pharming Group N.V. | $853.58M | $12.06 | — |
| CTY | CITY THERAPEUTICS, INC. | $846.44M | $17.50 | — |
| AKTS | Aktis Oncology, Inc. | $879.52M | $16.31 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $829.22M | $8.00 | — |
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
News headlines (Yahoo Finance, 1h cache)
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
2026-11-09 21:05 · Yahoo
Corvus (CRVS) Q3 2026 Earnings Call Transcript
2026-11-06 17:05 · Yahoo
Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...
2026-11-06 15:15 · Yahoo
Corvus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
2026-11-05 23:14 · Yahoo
Corvus: Q3 Earnings Snapshot
2026-11-05 21:36 · Yahoo
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hemato
2026-11-04 14:01 · Yahoo
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
2026-10-29 12:00 · Yahoo
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
2026-09-25 14:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.